Affinage

LPCAT3

Lysophospholipid acyltransferase 5 · UniProt Q6P1A2

Length
487 aa
Mass
56.0 kDa
Annotated
2026-06-10
67 papers in source corpus 21 papers cited in narrative 23 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 6/6 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

LPCAT3 is an integral membrane O-acyltransferase that selectively incorporates arachidonate (C20:4) and other polyunsaturated acyl chains into the sn-2 position of lysophospholipids, remodeling membrane phospholipid composition and thereby governing lipoprotein assembly, lipid absorption, membrane biophysics, and lipid peroxidation (PMID:25806685, PMID:35658397). Its enzymatic output—arachidonoyl phosphatidylcholine, phosphatidylethanolamine, and phosphatidylserine—is required for triglyceride secretion and VLDL lipidation, and tissue-specific deletion in intestine reduces polyunsaturated plasma-membrane phosphatidylcholines and surface levels of lipid transporters (NPC1L1, CD36, ABCA1, ABCG8), impairing lipid and cholesterol absorption, while hepatic deletion reduces plasma triglyceride (PMID:25806685, PMID:26828064). By supplying PUFA-phospholipids as substrates for oxidation, LPCAT3 is a central determinant of ferroptosis sensitivity and of oxidized/hydroperoxidized phospholipid accumulation in tissue injury (PMID:35658397, PMID:38019192). The same arachidonoyl-phospholipid supply feeds lipid raft organization and inflammatory signaling: LPCAT3 controls raft composition to permit NOX4 activation in adipocytes and TNFR1-complex translocation and NF-κB activation in endothelium, and it generates 12-LOX-derived procoagulant oxygenated phospholipids in platelets (PMID:39674322, PMID:36331295, PMID:41236634). LPCAT3 expression is directly induced by liver X receptor through a promoter LXRE (PMID:20837115) and by additional transcription factors including the YAP/ZEB/EP300 module, USF2, and SOX4 (PMID:37166352, PMID:40138726, PMID:42217103), and its mRNA is stabilized by METTL14-mediated m6A methylation (PMID:39836248). Across organs, LPCAT3-generated arachidonoyl/polyunsaturated phospholipids support cellular programs ranging from brown-fat mitochondrial bioenergetics and adipose expansion to endometrial decidualization (PMID:40503597).

Mechanistic history

Synthesis pass · year-by-year structured walk · 9 steps
  1. 2010 High

    Established a transcriptional control point for LPCAT3 by showing it is a direct LXR target, linking phospholipid remodeling to sterol/lipid sensing.

    Evidence In silico LXRE search with transactivation and EMSA assays in chicken and human hepatoma cells using LXR agonist T0901317

    PMID:20837115

    Open questions at the time
    • Did not address LPCAT3 enzymatic specificity or in vivo physiological consequence
    • Other transcription factors not yet examined
  2. 2015 High

    Defined LPCAT3's core enzymatic role—incorporating arachidonate into membrane phospholipids—and connected it to membrane biophysics and lipoprotein secretion.

    Evidence Intestine- and liver-specific knockout mice with FRAP membrane mobility, lipidomics, and VLDL characterization

    PMID:25806685

    Open questions at the time
    • Structural basis of acyl-chain selectivity not resolved
    • Direct biochemical reconstitution of substrate preference not shown
  3. 2016 High

    Identified the mechanistic link between LPCAT3-dependent membrane PUFA content and lipid absorption, showing transporter abundance depends on membrane composition.

    Evidence Inducible intestine- and liver-specific Lpcat3 knockout mice with lipid absorption assays and membrane transporter quantification; hepatic overexpression metabolic studies

    PMID:26828064 PMID:27110687

    Open questions at the time
    • How membrane PUFA content controls transporter surface levels mechanistically unclear
    • Overexpression β-oxidation link from a single lab
  4. 2018 High

    Connected LPCAT3 activity to cholesterol homeostasis and atherosclerosis, embedding it in the LXR efflux program in macrophages.

    Evidence Lpcat3-/- bone marrow transplantation into Ldlr-/- mice with lipidomics, cholesterol efflux assays, and lesion quantification

    PMID:29866392

    Open questions at the time
    • Direct causal chain from phospholipid changes to efflux defect not fully dissected
  5. 2020 High

    Demonstrated LPCAT3 acts on phosphatidylserine in the brain and operates in a coordinated cycle with the lyso-PS lipase ABHD12, extending its substrate range beyond PC/PE.

    Evidence Abhd12-/-;Lpcat3-/- double-knockout mice with brain lipidomics, auditory testing, and microgliosis histology

    PMID:32364701

    Open questions at the time
    • Quantitative contribution of LPCAT3 to total brain PS remodeling not isolated
  6. 2022 High

    Provided pharmacological tools and tied LPCAT3 directly to ferroptosis through its supply of C20:4 phospholipids, while hinting at a homodimeric enzyme architecture.

    Evidence High-throughput enzymatic screening, cell lipidomics versus LPCAT3-null cells, and ferroptosis assays; adipocyte lipid raft fractionation linking LPCAT3 to NOX4 activation

    PMID:35658397 PMID:36331295

    Open questions at the time
    • Biphasic inhibition/homodimer model inferred, not structurally confirmed
    • Only partial ferroptosis protection by inhibition indicates redundant routes
  7. 2023 Medium

    Expanded the transcriptional regulatory network with the YAP/ZEB/EP300 module and linked LPCAT3 to ferroptosis sensitization in cancer.

    Evidence ChIP, luciferase reporters, domain-mapping Co-IP, and LPCAT3/ACSL4 perturbation in LUAD cells and xenografts; coronaviral Mpro cleavage assays with catalytic mutagenesis showing ER stress induction

    PMID:37166352 PMID:37632038

    Open questions at the time
    • Single-lab transcriptional mechanism
    • Functional consequence of Mpro cleavage on LPCAT3 enzymatic activity not measured
  8. 2024 Medium

    Positioned LPCAT3 as a convergent downstream effector across diverse signaling inputs (MALT1/c-Myc, STAT1/IRF1, PPARγ) driving eicosanoid output, ferroptosis, and adipose biology.

    Evidence Chondrocyte and explant MALT1/c-Myc perturbation with DMM model; RNA-seq/ChIP-qPCR in IFN-γ-treated tumor cells; cell-free acyltransferase assay for 12-LOX eoxPL in platelets; adipocyte-specific knockout lipidomics (preprint)

    PMID:38471712 PMID:38519981 PMID:39674322

    Open questions at the time
    • Each pathway documented by a single lab
    • Direct versus indirect transcriptional control not always distinguished
  9. 2025 Medium

    Resolved LPCAT3's product-level mechanisms across organs—oxidized-PL substrates in liver injury, mitochondrial AA-PE bioenergetics, raft-controlled inflammation, ABCA1 stabilization, and PC(16:0-20:4)-dependent decidualization—and added m6A and SOX4/USF2 regulation.

    Evidence Liver-specific knockouts with APAP and MASH-HCC models; Me-RIP/RIP for METTL14 m6A; ChIP/luciferase for USF2 and SOX4; endothelial raft isolation; chondrocyte ubiquitination assays; hESC and BAT (preprint) lipidomic rescue experiments

    PMID:38019192 PMID:39836248 PMID:40138726 PMID:40503597 PMID:41072700 PMID:41236634 PMID:41951050 PMID:42217103

    Open questions at the time
    • Most organ-specific mechanisms from single labs
    • Specific phospholipid species mediating each phenotype only partially defined
    • Cross-tissue generalizability untested

Open questions

Synthesis pass · forward-looking unresolved questions
  • A high-resolution structure of LPCAT3 explaining acyl-chain selectivity and the proposed homodimeric catalytic behavior, and a unifying account of how a single phospholipid-remodeling enzyme is dialed to opposite outcomes (cytoprotection vs ferroptosis) in different tissues, remain unresolved.
  • No experimental structure in the corpus
  • Determinants selecting between membrane homeostasis and lipid-peroxidation outcomes not defined

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0016740 transferase activity 5 GO:0140096 catalytic activity, acting on a protein 1
Localization
GO:0005886 plasma membrane 3 GO:0005783 endoplasmic reticulum 2 GO:0005739 mitochondrion 1
Pathway
R-HSA-5357801 Programmed Cell Death 4 R-HSA-74160 Gene expression (Transcription) 4 R-HSA-1430728 Metabolism 3 R-HSA-8953897 Cellular responses to stimuli 3
Partners
ABCA1NOX4

Evidence

Reading pass · 23 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2015 LPCAT3 catalyzes the incorporation of arachidonate into membrane phospholipids and is required for triglyceride secretion. Intestine-specific or liver-specific Lpcat3 knockout mice show reduced plasma triglycerides, enterocyte lipid accumulation, and secretion of lipid-poor VLDL lacking arachidonoyl phospholipids. Mechanistic studies showed that Lpcat3 activity impacts membrane lipid mobility in living cells, providing a biophysical basis for arachidonoyl phospholipid requirements in lipoprotein lipidation. Tissue-specific knockout mice (intestine and liver), fluorescence microscopy for membrane lipid mobility (FRAP), lipidomics, plasma lipid measurements, VLDL characterization eLife High 25806685
2016 Intestine-specific Lpcat3 deficiency significantly reduces polyunsaturated phosphatidylcholines in enterocyte plasma membranes and reduces membrane levels of lipid transporters NPC1L1, CD36, ABCA1, and ABCG8, thereby reducing lipid absorption, cholesterol secretion, and plasma triglyceride, cholesterol, and phospholipid levels. Liver-specific Lpcat3 deficiency only reduces plasma triglyceride without other lipid changes or hepatic lipid accumulation. Small intestinal Lpcat3 deficiency has a dominant effect on plasma lipid metabolism compared to liver deficiency. Inducible intestine-specific (villin-Cre-ER(T2)) and liver-specific (AAV-Cre) Lpcat3 knockout mice, plasma lipid measurements, membrane protein quantification, lipid absorption assays The Journal of biological chemistry High 26828064
2010 LPCAT3 is a direct transcriptional target of the liver X receptor (LXR). A functional LXR response element (LXRE) was identified in the LPCAT3 promoter; LXR agonist T0901317 induces LPCAT3 expression in chicken and human hepatoma cells, and transactivation and EMSA assays confirmed direct LXR binding to the LXRE. Transcriptome profiling, in silico LXRE search, transactivation assays, electrophoretic mobility shift assay (EMSA), treatment with LXR agonist T0901317 Gene High 20837115
2018 LPCAT3 deficiency in macrophages causes major reductions in arachidonate content of phosphatidylcholines, phosphatidylethanolamines, and plasmalogens, alters cholesterol homeostasis (increased free-to-esterified cholesterol ratio, reduced cholesterol efflux), and inhibits LXR-regulated pathways including decreased Abca1, Abcg1, and ApoE mRNA. Hematopoietic LPCAT3 deficiency accelerates atherosclerosis in Ldlr-/- mice. Lpcat3-/- mice, bone marrow transplantation into Ldlr-/- mice, lipidomics, cholesterol efflux assays, qRT-PCR for LXR target genes, atherosclerotic lesion quantification Atherosclerosis High 29866392
2022 Small-molecule inhibitors of LPCAT3, discovered by high-throughput screening, inhibit LPCAT3 activity in a biphasic manner possibly reflecting differential activity at each subunit of an LPCAT3 homodimer. These inhibitors cause rapid suppression of C20:4 phospholipids and corresponding increases in C22:4 phospholipids in human cells, mirroring LPCAT3-null cells, and confer partial but incomplete protection from ferroptosis. High-throughput enzymatic screening, cell-based lipid profiling (lipidomics), LPCAT3-null cell comparison, ferroptosis assays ACS chemical biology High 35658397
2020 LPCAT3 incorporates arachidonoyl (C20:4) chains into phosphatidylserine (PS) in the brain. Genetic deletion of LPCAT3 in mice lacking the lyso-PS lipase ABHD12 blocks accumulation of C20:4 PS in the brain but produces hyper-increases in lyso-PS levels. These lipid changes correlate with exacerbated auditory dysfunction and brain microgliosis in mice lacking both ABHD12 and LPCAT3, revealing that ABHD12 and LPCAT3 coordinately regulate lyso-PS and C20:4 PS in the CNS. Double-knockout mice (Abhd12-/-; Lpcat3-/-), brain lipidomics, auditory function testing, brain microgliosis histology Biochemistry High 32364701
2016 Liver-specific overexpression of LPCAT3 (converting lysophosphatidylcholine to phosphatidylcholine) alleviates lysophospholipid inhibition of fatty acid β-oxidation in hepatocytes, improves postprandial hyperglycemia and glucose tolerance, reduces VLDL production, and elevates large apoE-rich HDL in plasma. Adenovirus-mediated hepatic overexpression in C57BL/6 mice, glucose tolerance tests after lipid-glucose mixed meal, VLDL/HDL characterization, fatty acid β-oxidation assays in hepatocytes Nutrition & diabetes Medium 27110687
2023 LPCAT3 transcription is regulated by YAP, ZEB, and EP300. ZEB directly binds the LPCAT3 promoter in the -1600 to -1401 nt region in a YAP-dependent manner; YAP and ZEB interact via ZEB's zinc-finger cluster domain and YAP's WW domain; EP300 binds YAP via its Bromo domain and ZEB via its CBP/p300-HAT domain, and induces H3K27Ac at the LPCAT3 locus. LPCAT3 and ACSL4 sensitize lung adenocarcinoma cells to ferroptosis. ChIP assays, luciferase reporter assays, domain mutagenesis, Co-IP, LPCAT3/ACSL4 overexpression and knockout in LUAD cell lines and xenograft models Antioxidants & redox signaling Medium 37166352
2024 MALT1 upregulates LPCAT3 expression in chondrocytes via c-Myc, driving incorporation of arachidonic acid into membranes and subsequent eicosanoid production, MMP3 and ADAMTS5 expression, and cytokine secretion. Pharmacological inhibition of MALT1 or siRNA knockdown of LPCAT3 suppresses IL-1β-induced cartilage catabolism and attenuates osteoarthritis in a mouse DMM model. MALT1 overexpression/pharmacological inhibition in chondrocytes and human cartilage explants, LPCAT3 siRNA-lipid nanoparticles, c-Myc inhibition, DMM mouse model, cytokine/eicosanoid measurements Cell communication and signaling Medium 38519981
2024 LPCAT3 is transcriptionally regulated by USF2 in the context of sepsis-induced acute kidney injury. USF2 binds the LPCAT3 promoter (confirmed by ChIP-qPCR and dual-luciferase assay) to upregulate LPCAT3, which promotes ferroptosis via the NRF2/HO-1/GPX4 pathway. LPCAT3 knockdown in vivo ameliorates sepsis-AKI. ChIP-qPCR, dual-luciferase reporter assay, LPCAT3 knockdown (siRNA and AAV-shRNA in vivo), LPS-induced AKI model, ferroptosis marker quantification Shock Medium 40138726
2025 METTL14 (an m6A writer) promotes LPCAT3 mRNA m6A methylation, increasing LPCAT3 mRNA stability and expression, which drives ferroptosis in sepsis-induced AKI. METTL14 knockdown reduces m6A and mRNA levels of LPCAT3, and LPCAT3 overexpression reverses the ferroptosis-protective effects of METTL14 silencing. Me-RIP assay for m6A on LPCAT3 mRNA, RIP assay, dual-luciferase reporter assay, siRNA knockdown of METTL14, LPCAT3 overexpression rescue, LPS-induced AKI model in vitro and in vivo Molecular genetics and genomics Medium 39836248
2024 IFN-γ-induced STAT1-IRF1 signaling upregulates LPCAT3 expression, and LPCAT3 knockdown impairs ferroptosis induced by mefloquine combined with IFN-γ in melanoma and lung cancer cells, establishing LPCAT3 as a downstream effector of the IFN-γ-STAT1-IRF1 pathway in ferroptosis sensitization. RNA sequencing, qRT-PCR, western blotting, ChIP-qPCR, LPCAT3 knockdown, cytotoxicity and ferroptosis assays, animal experiments Journal for immunotherapy of cancer Medium 38471712
2023 Coronaviral main protease (Mpro) of PEDV and MERS-CoV (but not HCoV-OC43 or HCoV-HKU1) cleaves LPCAT3 independently of Mpro catalytic activity. LPCAT3 cleavage by Mpro induces ER stress (upregulation of CHOP and GRP78), suggesting a mechanism for gastrointestinal symptoms in coronavirus infections. Exogenous gene expression of Mpro, protease inhibitor experiments, mutagenesis of Mpro catalytic site, qRT-PCR, gene knockdown, western blotting Viruses Medium 37632038
2024 LPCAT3 is the acyltransferase responsible for generating 12-LOX-derived diacyl enzymatically oxygenated phospholipids (eoxPL) in platelets. LPCAT3 inhibition selectively prevented 12-LOX-derived diacyl-eoxPL generation in a cell-free acyltransferase assay, identifying LPCAT3 as a key enzyme in procoagulant phospholipid biosynthesis. LPCAT3 pharmacological inhibitor, cell-free acyltransferase assay, platelet lipidomics, ASCVD patient cohort platelet measurements Journal of lipid research Medium 39674322
2025 LPCAT3 deficiency in liver (liver-specific knockout) reduces accumulation of oxidized and hydroperoxidized phospholipids and ameliorates acetaminophen-induced acute liver injury, demonstrating that LPCAT3-generated arachidonoyl phospholipids are substrates for oxidative liver injury. LPCAT3 deficiency also promotes APAP detoxification by facilitating glutathione conjugation of NAPQI. Liver-specific Lpcat3 knockout mice, APAP overdose model, lipidomics (oxidized/hydroperoxidized PL quantification), serum liver injury markers, survival analysis, glutathione conjugation assay FASEB journal High 38019192
2022 LPCAT3 deficiency in adipocytes increases NOX4 translocation to lipid rafts, facilitating NOX enzyme activity and reactive oxygen species generation, which promotes palmitic acid-induced inflammation and lipolysis. LPCAT3 overexpression has anti-inflammatory and anti-lipolytic effects in adipocytes by reducing membrane polyunsaturated phosphatidylcholine content. Lpcat3 knockdown and overexpression in 3T3-L1 adipocytes, NOX4 localization by lipid raft fractionation, ROS measurement, lipid profiling, inflammatory cytokine assays Acta biochimica et biophysica Sinica Medium 36331295
2025 LPCAT3 stabilizes ABCA1 protein through post-translational regulation in chondrocytes. Gene silencing of LPCAT3 downregulates ABCA1 protein through ubiquitination and degradation, which increases intracellular retention of methylprednisolone. LXR agonist T0901317 reverses LPCAT3-induced changes in ABCA1 and steroid retention. LPCAT3 siRNA in chondrocytes, ABCA1 protein stability assays, ubiquitination assays, intracellular steroid retention measurements, intra-articular siRNA liposome administration in DMM mouse model International journal of biological macromolecules Medium 41072700
2025 LPCAT3 silencing in endothelial cells inhibits TNFα-induced translocation and ubiquitination of TNFR1-signaling complex into lipid rafts, attenuating NF-κB activation, cell-adhesion molecule synthesis, cytokine production, and leukocyte adhesion. LPCAT3 controls lipid raft composition by incorporating arachidonic acid, and its inhibition results in replacement of AA with EPA/DHA in PC and PE, reducing eicosanoid production. RNAi-dependent LPCAT3 silencing in endothelial cells, lipid raft isolation, TNFR1 localization assays, NF-κB activation assays, LPCAT3 siRNA lipid nanoparticles in high-fat diet atherosclerosis mouse model Inflammation research Medium 41236634
2025 LPCAT3 deficiency in liver triggers upregulation of protein disulfide isomerase (Pdi) and endoplasmic reticulum oxidoreductase 1 alpha (Ero1α), leading to mitochondrial accumulation of H2O2 and Ca2+ and impaired mitochondrial oxidative phosphorylation, accelerating MASH-to-HCC progression. Supplementing PC(18:2/18:2) in LPCAT3-knockdown cells reversed Pdi-Ero1α upregulation and alleviated mitochondrial dysfunction. Liver-specific Lpcat3 knockout mice, MASH-HCC diet model, lipidomics, proteomics, AAV-mediated LPCAT3 overexpression, mitochondrial function assays, PC(18:2/18:2) supplementation rescue experiment Journal of advanced research Medium 41951050
2025 LPCAT3 acts as a cold-regulated O-acyltransferase driving selective accumulation of arachidonoyl-phosphatidylethanolamine (AA-PE) in brown adipose tissue mitochondria. AA-PE partitions at the COX4I1 interface of Cytochrome c oxidase, enhancing electron transport chain efficiency. Fat-specific Lpcat3-knockout mice have defective BAT thermogenesis and cold tolerance despite intact β-adrenergic signaling and UCP1 function. Fat-specific Lpcat3 knockout mice, cold exposure experiments, lipid-based proteomics, molecular dynamics simulations, bioenergetic analyses, mitochondrial fractionation bioRxivpreprint Medium
2024 PPARγ supports hypertrophic expansion of adipose tissue through transcriptional control of LPCAT3, which enriches diet-derived omega-6 PUFAs (particularly arachidonoyl-PE) in the phospholipidome at the ER-lipid droplet interface. Adipocyte-specific Lpcat3 knockout leads to dysfunctional triglyceride storage, aberrant lipolysis, and a futile lipid cycle that increases energy expenditure. Adipocyte-specific Lpcat3 knockout mice, high-fat diet feeding, lipidomics at ER-lipid droplet interface, ATGL-dependent hydrolysis assays, energy expenditure measurements bioRxivpreprint Medium
2025 In endometrial stromal cells (hESCs), LPCAT3 knockdown reduces decidualization markers, halts epithelioid-like morphological changes, and decreases PC(16:0-20:4) levels. Reintroducing PC(16:0-20:4) rescues the decidualization defect and premature senescence caused by LPCAT3 knockdown, identifying PC(16:0-20:4) as the key lipid product of LPCAT3 mediating hESC decidualization. LPCAT3 knockdown and overexpression in hESCs, phospholipid profiling (lipidomics), PC(16:0-20:4) supplementation rescue, decidualization marker quantification, cell cycle analysis, senescence assays FASEB journal Medium 40503597
2024 SOX4 binds the LPCAT3 promoter and enhances its transcription (confirmed by ChIP and dual-luciferase assay), upregulating LPCAT3 to promote ferroptosis in caerulein-induced acute pancreatitis. LPCAT3 overexpression partially reverses the protective effects of SOX4 knockdown. ChIP assay, dual-luciferase reporter assay, shRNA-mediated SOX4 knockdown, LPCAT3 overexpression rescue, ferroptosis marker quantification in pancreatic acinar cells Digestive diseases and sciences Medium 42217103

Source papers

Stage 0 corpus · 67 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2015 Lpcat3-dependent production of arachidonoyl phospholipids is a key determinant of triglyceride secretion. eLife 193 25806685
2022 LPCAT3 Inhibitors Remodel the Polyunsaturated Phospholipid Content of Human Cells and Protect from Ferroptosis. ACS chemical biology 127 35658397
2023 LPCAT3 Is Transcriptionally Regulated by YAP/ZEB/EP300 and Collaborates with ACSL4 and YAP to Determine Ferroptosis Sensitivity. Antioxidants & redox signaling 97 37166352
2011 Automated NMR relaxation dispersion data analysis using NESSY. BMC bioinformatics 67 22032230
2024 Mefloquine enhances the efficacy of anti-PD-1 immunotherapy via IFN-γ-STAT1-IRF1-LPCAT3-induced ferroptosis in tumors. Journal for immunotherapy of cancer 54 38471712
1975 Association between the C3F gene and atherosclerotic vascular diseases. Human heredity 44 1184013
2022 The expanding role of lyso-phosphatidylcholine acyltransferase-3 (LPCAT3), a phospholipid remodeling enzyme, in health and disease. Current opinion in lipidology 43 35165232
2018 LPCAT3 deficiency in hematopoietic cells alters cholesterol and phospholipid homeostasis and promotes atherosclerosis. Atherosclerosis 40 29866392
1978 Association between coronary heart disease and the C3F-gene in essential hypertension. Circulation 40 688571
2024 A pH responsive nanocomposite for combination sonodynamic-immunotherapy with ferroptosis and calcium ion overload via SLC7A11/ACSL4/LPCAT3 pathway. Exploration (Beijing, China) 39 40040833
2016 Small Intestine but Not Liver Lysophosphatidylcholine Acyltransferase 3 (Lpcat3) Deficiency Has a Dominant Effect on Plasma Lipid Metabolism. The Journal of biological chemistry 37 26828064
2010 Regulation of LPCAT3 by LXR. Gene 35 20837115
2022 Research progress in the role and mechanism of LPCAT3 in metabolic related diseases and cancer. Journal of Cancer 34 35711841
2024 Gastrodin: Modulating the xCT/GPX4 and ACSL4/LPCAT3 pathways to inhibit ferroptosis after ischemic stroke. Phytomedicine : international journal of phytotherapy and phytopharmacology 29 39731833
2020 ABHD12 and LPCAT3 Interplay Regulates a Lyso-phosphatidylserine-C20:4 Phosphatidylserine Lipid Network Implicated in Neurological Disease. Biochemistry 25 32364701
2022 The regulation of LPCAT3 by miR-124-3p.1 in acute kidney injury suppresses cell proliferation by disrupting phospholipid metabolism. Biochemical and biophysical research communications 23 35286868
1984 Polymorphism of complement C3 in chronic inflammatory bowel disease. Predominance of the C3F gene in Crohn's disease. Acta medica Scandinavica 23 6731047
1989 Factor C3f is a spasmogenic fragment released from C3b by factors I and H: the heptadeca-peptide C3f was synthesized and characterized. Molecular immunology 21 2531841
1981 Association between the C3F-gene and essential hypertension. Clinical science (London, England : 1979) 21 7318338
2016 Liver-specific overexpression of LPCAT3 reduces postprandial hyperglycemia and improves lipoprotein metabolic profile in mice. Nutrition & diabetes 19 27110687
2024 Research progress, challenges and perspectives of phospholipids metabolism in the LXR‑LPCAT3 signaling pathway and its relation to NAFLD (Review). International journal of molecular medicine 18 38362962
1995 Comparison of the binding of C3S and C3F to complement receptors types 1, 2, and 3. Journal of immunology (Baltimore, Md. : 1950) 17 7730637
2024 Inhibition of the MALT1-LPCAT3 axis protects cartilage degeneration and osteoarthritis. Cell communication and signaling : CCS 15 38519981
2024 Lactate-Dependent HIF1A Transcriptional Activation Exacerbates Severe Acute Pancreatitis Through the ACSL4/LPCAT3/ALOX15 Pathway Induced Ferroptosis. Journal of cellular biochemistry 13 39676583
1989 The difference between human C3F and C3S results from a single amino acid change from an asparagine to an aspartate residue at position 1216 on the alpha-chain of the complement component, C3. Journal of immunology (Baltimore, Md. : 1950) 13 2473125
2025 Activation of gut metabolite ACSL4/LPCAT3 by microplastics in drinking water mediates ferroptosis via gut-kidney axis. Communications biology 12 39930042
2025 Methyltransferase-like 14 promotes ferroptosis in sepsis-induced acute kidney injury via increasing the m6A methylation modification of LPCAT3. Molecular genetics and genomics : MGG 11 39836248
2023 Ferroptosis-related genes LPCAT3 and PGD are potential diagnostic biomarkers for osteoarthritis. Journal of orthopaedic surgery and research 11 37723556
2022 Qinggan Huoxue Recipe Alleviates Alcoholic Liver Injury by Suppressing Endoplasmic Reticulum Stress Through LXR-LPCAT3. Frontiers in pharmacology 11 35431945
2022 Lysophosphatidylcholine acyltransferase 3 (LPCAT3) mediates palmitate-induced inflammation in macrophages of large yellow croaker (Larimichthys crocea). Fish & shellfish immunology 10 35526799
1997 The comorbid association of migraine with osteoarthritis and hypertension: complement C3F and Berkson's bias. Cephalalgia : an international journal of headache 10 9051331
1986 The C3-F gene in patients with intracranial saccular aneurysms. Acta neurologica Scandinavica 9 3825492
2024 LPCAT3/LPLAT12 deficiency in the liver ameliorates acetaminophen-induced acute liver injury. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 8 38019192
2024 Liver X receptor agonist upregulates LPCAT3 in human aortic endothelial cells. Frontiers in physiology 8 38694208
2024 Z-Ligustilide restricts rabies virus replication by inducing ferroptosis through the ACSL4-LPCAT3-POR pathway. Veterinary microbiology 8 39316946
2017 C3f is a potential tool for the staging of osteoarthritis. Journal of biological regulators and homeostatic agents 8 29181954
1999 nessy, an evolutionary conserved gene controlled by Hox proteins during Drosophila embryogenesis. Mechanisms of development 8 10446276
2024 Methylation Regulation of LPCAT3 Improves Osteoarthritis by Regulating ACSL4 to Inhibit Chondrocyte Ferroptosis. Critical reviews in eukaryotic gene expression 7 38073444
2024 LPCAT3 exacerbates early brain injury and ferroptosis after subarachnoid hemorrhage in rats. Brain research 7 38484924
2019 Dopamine D2 Receptor Occupancy Estimated From Plasma Concentrations of Four Different Antipsychotics and the Subjective Experience of Physical and Mental Well-Being in Schizophrenia: Results From the Randomized NeSSy Trial. Journal of clinical psychopharmacology 7 31688449
2014 C3F gene mutation is involved in the susceptibility to pre-eclampsia. Archives of gynecology and obstetrics 6 25322978
2025 Ginsenoside RK1 Promotes Hepatic Stellate Cell Glycolysis-Mediated Ferroptosis by Activating the HK2/ACSL4/LPCAT3/ALOX5 Signaling Pathway. Journal of agricultural and food chemistry 5 40570179
2025 Arachidonic acid induces ferroptosis in hepatocellular carcinoma via the SIRT5-ACSL4/LPCAT3/ALOX15 axis, leading to lipid peroxidation and mitochondrial dysfunction. Phytomedicine : international journal of phytotherapy and phytopharmacology 5 41175589
2022 Lpcat3 deficiency promotes palmitic acid-induced 3T3-L1 mature adipocyte inflammation through enhanced ROS generation. Acta biochimica et biophysica Sinica 5 36331295
2024 LPCAT3 regulates the proliferation and metastasis of serous ovarian cancer by modulating arachidonic acid. Translational oncology 4 39733744
2023 Coronaviral Main Protease Induces LPCAT3 Cleavage and Endoplasmic Reticulum (ER) Stress. Viruses 4 37632038
2024 Aspirin modulates generation of procoagulant phospholipids in cardiovascular disease, by regulating LPCAT3. Journal of lipid research 3 39674322
2025 USF2 EXACERBATES SEPSIS-INDUCED ACUTE KIDNEY INJURY AND FERROPTOSIS THROUGH LPCAT3-MEDIATED NRF2/HO-1/GPX4 PATHWAY. Shock (Augusta, Ga.) 2 40138726
2025 Laminar shear stress promotes accumulation of polyunsaturated fatty acid in aortic endothelial cells through upregulation of LPCAT3 enzyme activity. Biochimica et biophysica acta. Molecular and cell biology of lipids 2 40414415
2025 Amlodipine and perindopril modulate miR-874-3p expression to regulate ferroptosis-linked LPCAT3/LACS4/GPX4 Axis and gut dysbiosis in metabolic-associated steatohepatitis. International immunopharmacology 2 40782429
2025 LPCAT3-dependent remodeling of the phospholipids and lipid rafts is essential for vascular proinflammatory signaling and the development of atherosclerosis. Inflammation research : official journal of the European Histamine Research Society ... [et al.] 2 41236634
2024 Inhibition of LPCAT3 exacerbates endoplasmic reticulum stress and HBV replication. International immunopharmacology 2 39423656
2026 KLF1 Exerts Pro-Tumour Role in Liver Cancer via Inhibiting ACSL4/LPCAT3-Regulated Ferroptosis. Journal of cellular and molecular medicine 1 41656392
2025 KLF6 enhances ferroptosis in S-AKI through the NCOA4/ACSL4/LPCAT3 axis. International immunopharmacology 1 40811945
2025 LPCAT3-ABCA1 axis regulates the dose-sparing effects of steroid drugs in osteoarthritis in mice. International journal of biological macromolecules 1 41072700
2026 Exosomes from young healthy human plasma ameliorate sepsis-induced cardiomyopathy by inhibiting ferroptosis via the miR-3130-3p/LPCAT3 axis. Free radical biology & medicine 0 41539372
2026 Curcumin nanoparticles attenuate sepsis-induced myocardial injury by modulating the Nrf2/HO-1/SLC7A11/GPX4 and ACSL4/LPCAT3 pathways. Pathology, research and practice 0 41619537
2026 Liver specific-inhibition of LPCAT3 ameliorates metabolic dysfunction-associated steatotic liver disease. Journal of molecular medicine (Berlin, Germany) 0 41632287
2026 [Effect of electroacupuncture on ACSL4/LPCAT3/ALOX15 signaling pathway of ferroptosis in rats with premature ovarian insufficiency]. Zhen ci yan jiu = Acupuncture research 0 41735063
2026 LPCAT3 deficiency Drives phospholipid remodeling and mitochondrial oxidative dysfunction to accelerate MASH-HCC development. Journal of advanced research 0 41951050
2026 LPCAT3 as a Potential Drug Target for Ultraviolet Radiation-Induced Cataract: Insights From Multiomics Analysis. The Kaohsiung journal of medical sciences 0 42028922
2026 SOX4 Knockdown Represses Pancreatic Acinar Cells Ferroptosis in Acute Pancreatitis Through Reducing LPCAT3 Expression. Digestive diseases and sciences 0 42217103
2026 Gut microbiota-derived short-chain fatty acids attenuate placental ferroptosis and insulin resistance in gestational diabetes via the ACSL4/LPCAT3 pathway. Frontiers in microbiology 0 42245515
2026 Lipid droplet associated protein HILPDA promotes hypoxia-induced ferroptosis by driving LPCAT3-mediated polyunsaturated phospholipids enrichment. PloS one 0 42258477
2025 Deficiency of LPCAT3 Compromises Endometrial Stromal Cell Decidualization in Polycystic Ovary Syndrome. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 0 40503597
2025 The Role and Mechanism of CircCOG5 in Regulating Ferroptosis in Ovarian Cancer Cells by Targeting miR-532-3p/LPCAT3. Biochemical genetics 0 40634790
2012 [The effects of complement C3f segment on expression and secretion of collagen I, III and transforming growth factor-beta1 in human embryonic lung fibroblast]. Zhonghua lao dong wei sheng zhi ye bing za zhi = Zhonghua laodong weisheng zhiyebing zazhi = Chinese journal of industrial hygiene and occupational diseases 0 22730691

Missed literature

Know a paper Affinage missed for LPCAT3? Flag it for the maintainers and the community.

No submissions yet.